Allogene Therapeutics, Inc.

Equities

ALLO

US0197701065

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
4.47 USD +0.22% Intraday chart for Allogene Therapeutics, Inc. +2.05% +39.25%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Allogene Therapeutics, Inc.(NasdaqGS:ALLO) added to S&P Biotechnology Select Industry Index CI
Allogene Therapeutics Files $500 Million Mixed Shelf MT
Transcript : Allogene Therapeutics, Inc., Q4 2023 Earnings Call, Mar 14, 2024
Allogene Therapeutics Q4 Loss Narrows, Revenue Drops MT
Allogene Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Allogene Therapeutics to Restate Financial Statements Due to Accounting Adjustments MT
Allogene Therapeutics, Inc. Announces Restate Financial Statements for the Years Ended December 31, 2020, 2021 and 2022 and Interim Quarters During 2022 and 2023 CI
HC Wainwright Adjusts Allogene Therapeutics Price Target to $10 From $12, Maintains Buy Rating MT
Transcript : Allogene Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 08:15 AM
North American Morning Briefing : Boeing Drags -2- DJ
B. Riley Adjusts Allogene Therapeutics' PT to $10 From $15 on Heels of Announced Strategic Shift to Focus on New Study for Large B-cell Lymphoma, Keeps Buy Rating MT
Allogene Therapeutics to Lay off 22% of Workforce; Partners With Foresight to Develop in Vitro Diagnostic MT
Allogene Therapeutics Planning to Cut Roughly 22% of Workforce MT
JMP Securities Downgrades Allogene Therapeutics to Market Perform From Market Outperform MT
Allogene to cut 22% of its workforce RE
Transcript : Allogene Therapeutics, Inc. - Special Call
Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-Based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma CI
Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of Car T Led by ALPHA3 CI
Allogene Therapeutics, Inc.(NasdaqGS:ALLO) dropped from S&P Biotechnology Select Industry Index CI
Allogene Therapeutics, Inc. Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 CI
Citigroup Starts Allogene Therapeutics With Buy Rating, $7 Price Target MT
HC Wainwright Cuts Price Target on Allogene Therapeutics to $12 From $23, Keeps Buy Rating MT
Allogene Therapeutics Shares Jump After Reporting Preclinical Data on AlloCAR T Product Candidate for Cancer MT
Allogene Therapeutics, Inc. Presents Preclinical Data on Next Generation Cloak and Dagger Technologies At the Society for Immunotherapy of Cancer Annual Meeting CI
Allogene Therapeutics, Inc. Presents Preclinical Data on Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 At the Society for Immunotherapy of Cancer Annual Meeting CI
Chart Allogene Therapeutics, Inc.
More charts
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on four core programs: Large B-Cell Lymphoma (LBCL), Chronic Lymphocytic Leukemia (CLL), Autoimmune Disease and Renal Cell Carcinoma. It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL and CLL. Its pipeline also includes ALLO-316, ALLO-329 and ALLO-647.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
4.47 USD
Average target price
11.66 USD
Spread / Average Target
+160.81%
Consensus
  1. Stock
  2. Equities
  3. Stock Allogene Therapeutics, Inc. - Nasdaq
  4. News Allogene Therapeutics, Inc.
  5. Goldman Sachs Adjusts Allogene Therapeutics' Price Target to $33 From $32, Maintains Buy Rating